Early treatment study
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed)
COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxych loroquine and Azithromycin: A Retrospective Case Series Study
79% lower mortality and 82% lower hospitalization with early HC
No cardiac side effects. Retrospective 518 patients (141 treated, 377 control).
death, ↓79.4%, p=0.12
hospitalization, ↓81.6%, p<0.001
(odds ratio converted to relative risk)
Please send us corrections, updates, or comments.